Author： Younis Firas Kariv Naam Nachman Rachel Zangen Sara Rosenthal Talma
Publisher： Informa Healthcare
ISSN： 1064-1963
Source： Clinical and Experimental Hypertension, Vol.29, Iss.6, 2007-08, pp. : 419-426
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The antihypertensive and hypoglycemic effects of telmisartan, which has dual angiotensin II antagonist-PPAR-γ agonist properties, was studied in Cohen-Rosenthal Diabetic Hypertensive rats (CRDH), a model in which hypertension, insulin resistance, and diabetes co-exist. CRDH, Cohen-diabetic rats (CDR), and SHR received telmisartan (3 mg/kg/day in drinking water) for five months. Telmisartan significantly lowered systolic and diastolic BP in SHR and CRDH, independent of body weight, and remained fairly constant in controls throughout the experiment. Blood glucose levels fell rapidly in the treated animals and remained steady in controls. Results indicate that telmisartan is a prototype of a new approach to treating coexisting diabetes and hypertension.
Related content
Pituitary, Vol. 7, Iss. 4, 2004-12 ,pp. :
Access to resources
Recommend
By Yilmaz Mahmut Sonmez Alper Caglar Kayser Gok Deniz Eyileten Tayfun Yenicesu Müjdat Acikel Cengizhan Bingol Necati Kilic Selim Oguz Yusuf Vural Abdulgaffar
Endocrine Journal, Vol. 25, Iss. 3, 2004-12 ,pp. :
By Rollins Michael Sudarshan Sharon Firpo Matthew Etherington Brooke Hart Brandon Jackson Heidi Jackson Jeffrey Emerson Lyska Yang David Mulvihill Sean Glasgow Robert
Journal of Gastrointestinal Surgery, Vol. 10, Iss. 8, 2006-08 ,pp. :
Clinical and Experimental Hypertension, Vol. 35, Iss. 5, 2013-08 ,pp. :